Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00692159 · ClinicalTrials.gov registry record · Phase 1
Study of TRC102 in Combination With Pemetrexed in Cancer Patients
A Phase 1 study, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00692159 is a Phase 1 study that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 28 participants.
The verdict
NCT00692159, a Phase 1 study, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is being performed to evaluate the safety and tolerability of TRC102 in combination with Alimta. In addition to safety, this study will also evaluate pharmacokinetics and tumor response.
Interventions
- DRUG TRC102 + pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00692159
The ClinicalTrials.gov registry entry for NCT00692159 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tracon Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRC102 + pemetrexed is the first listed.
NCT00692159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00692159 about?
NCT00692159 is a clinical study titled "Study of TRC102 in Combination With Pemetrexed in Cancer Patients". This study is being performed to evaluate the safety and tolerability of TRC102 in combination with Alimta. In addition to safety, this study will also evaluate pharmacokinetics and tumor response.
What is the current status of trial NCT00692159?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2008-06. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00692159?
The interventions under investigation include: TRC102 + pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00692159?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.